Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 11
Submit an article Journal homepage
2,465
Views
18
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma

Kevin BarleyHematology and Oncology, Multiple Myeloma Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
,
Wei HeHematology and Oncology, Multiple Myeloma Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
,
Shradha AgarwalDepartment of Allergy and Immunology, Multiple Myeloma Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA
,
Sundar JagannathHematology and Oncology, Multiple Myeloma Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
&
Ajai ChariHematology and Oncology, Multiple Myeloma Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Correspondence[email protected]
Pages 2510-2515 | Received 13 Oct 2015, Accepted 27 Jan 2016, Published online: 04 Mar 2016

References

  • Hall VC, El-Azhary RA, Bouwhuis S, et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol. 2003;48:548–552.
  • Nardone B, Wu S, Garden BC, et al. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk. 2013;13:424–429.
  • Patrizi A, Venturi M, Dika E, et al. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. Cutan Ocul Toxicol. 2013;33:1–2
  • Sviggum HP, Davis MD, Rajkumar SV, et al. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol. 2006;142:1298–1302.
  • Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013;122:2799–2806.
  • Castaneda CP, Brandenburg NA, Bwire R, et al. Erythema multiforme/Stevens–Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J Clin Oncol. 2009;27:156–157.
  • Michot C, Guillot B, Dereure O. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents. Dermatology. 2010;220:49–50.
  • Perez-Paredes MG, Rodriguez-Prieto MA, Ruiz-Gonzalez I, et al. Lenalidomide-induced photosensitivity. Photodermatol Photoimmunol Photomed. 2013;29:334–336
  • Yildirim ND, Ayer M, Kucukkaya RD, et al. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. Jpn J Clin Oncol. 2007;37:704–707.
  • Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug allergy. Allergy. 2014;69:420–437.
  • Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA. 2012;109:9959–9964.
  • Penna G, Allegra A, Romeo G, et al. Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602. Acta Oncol. 2012;51:944–947.
  • Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. 2013;32:4191–4202.
  • Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305–309.
  • Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–305.
  • Lee MJ, Wickner P, Fanning L, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014;167:127–131.
  • Balagula Y, Rosen A, Tan BH, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012;118:5078–5083.
  • Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.
  • Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013;62:39–49.
  • Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 2013;162:313–325.
  • Liu HB, Wu Y, Lv TF, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013;8:e55128.
  • Revlimid(R) [package insert]. Summit, NJ: Celgene Corporation; February, 2015; [cited 2015 Dec 28]. Available from: http://www.revlimid.com/wp-content/uploads/full-prescribing-information.pdf.
  • Thalomid(R) [package insert]. Summit, NJ: Celgene Corporation; August, 2015; [cited 2015 Dec 28]. Available from: http://www.thalomid.com/pdf/Thalomid_PI.pdf.
  • Pomalyst(R) [package insert]. Summit, NJ: Celgene Corporation; April, 2015; [cited 2015 Dec 28]. Available from: http://www.pomalyst.com/wp-content/uploads/prescribing_information.pdf.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.